Purpose: To explore miR-195-5p expression and prognostic value in advanced gastric cancer (AGC) patients after chemotherapy.
Methods: 114 patients in total with AGC admitted to our hospital undergoing chemotherapy created the gastric cancer group, and 100 simultaneous healthy subjects undergoing physical examination created the normal group. MiR-195-5p level in both groups was detected.
Results: miR-195-5p level was evidently lower in the gastric cancer group, and miR-195-5p could be used in diagnosing gastric cancer patients. miR-195-5p was significantly associated with clinical stage and grade of differentiation. It was found that carcinoembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA19.9) were significantly negatively associated with miR-195-5p level before treatment in patients with AGC. Subjects were divided into effective group and ineffective group based on the therapeutic effect, mir-195-5p level in the ineffective group was notably lower than that in the effective group, and the serum miR-195-5p level was available for efficacy prediction. Patients were separated to high expression group and low expression group based on the median of the mir-195-5p expression. High expression group had remarkably better survival in comparison with the low expression group, and miR-195-5P expression of dead patients was lower than that of the surviving patients.
Conclusion: Serum miR-195-5p is decreased in AGC patients, and can be effectively utilized as a biomarker for the diagnosis and prognosis of patients with gastric cancer.